Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

Recombinase efficiency increases allow Qi Biodesign to insert 20-30 kb (5 or 6 genes) at one time at one location across a variety of different crop genetics. In addition, a large team at Qi Biodesign ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

Could it also give us better tomatoes, a hybrid woolly mammoth-elephant that could help save Arctic forests, and perhaps even ...

A vast search of natural diversity has led scientists at MIT's McGovern Institute and the Broad Institute of MIT and Harvard ...

Looking for the best graphics cards for video editing can be a daunting task, especially given the sheer number of options existing in today's ever-expanding GPU market. As someone who reviews ...

Multiplex genome editing, particularly through CRISPR technologies, offers a promising solution to accelerate the development of climate-resilient traits in woody plants. By simultaneously targeting ...

The power of gene editing is that it is possible to make small changes to the genome and get results quickly. While some companies in the agbio space have embraced CRISPR-based editing ...

This review highlights the potential of gene editing to develop climate-resilient crops, contributing to food security and sustainable agriculture. Keywords: Genome editing, Climate-resilience crops, ...